Pasvenskaite Agne, Liutkeviciene Rasa, Gedvilaite Greta, Vilkeviciute Alvita, Liutkevicius Vykintas, Uloza Virgilijus
Department of Otorhinolaryngology, Lithuanian University of Health Sciences (LUHS), A. Mickeviciaus 9, LT 44307, Kaunas, Lithuania.
Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), Kaunas, Lithuania.
Discov Oncol. 2023 Jan 22;14(1):8. doi: 10.1007/s12672-023-00619-0.
Results of laryngeal squamous cell carcinoma (LSCC) treatment and the 5 year survival rate of these patients remain poor. To purify therapeutic targets, investigation of new specific and prognostic blood-based markers for LSCC development is essential.
In the present study, we evaluated five single nucleotide polymorphisms (SNPs): IL1RAP rs4624606, IL1RL1 rs1041973, IL-6 rs1800795, BLK rs13277113, and TIMP3 rs9621532, and determined their associations with the patients' 5 year survival rate. Also, we performed a detailed statistical analysis of different LSCC patients' characteristics impact on their survival rate.
Three hundred fifty-three LSCC patients and 538 control subjects were included in this study. The multivariable Cox regression analysis revealed a significant association between patients' survival rate and distribution of IL1RAP rs4624606 variants: patients carrying AT genotype at IL1RAP rs4624606 had a lower risk of death (p = 0.044). Also, it was revealed that tumor size (T) (p = 0.000), tumor differentiation grade (G) (p = 0.015), and IL1RAP rs4624606 genotype (p = 0.044) were effective variables in multivariable Cox regression analysis prognosing survival of LSCC patients. The specific-LSCC 5 year survival rate was 77%.
In summary, our findings indicate that the genotypic distribution of IL1RAP rs4624606 influences the 5 year survival rate of LSCC patients. The results of the present study facilitate a more complete understanding of LSCC at the biological level, thus providing the base for the identification of new specific and prognostic blood-based markers for LSCC development.
喉鳞状细胞癌（LSCC）的治疗效果及这些患者的5年生存率仍然较差。为了纯化治疗靶点，研究用于LSCC发展的新的特异性和预后性血液标志物至关重要。
在本研究中，我们评估了五个单核苷酸多态性（SNP）：IL1RAP rs4624606、IL1RL1 rs1041973、IL - 6 rs1800795、BLK rs13277113和TIMP3 rs9621532，并确定它们与患者5年生存率的关联。此外，我们对不同LSCC患者的特征对其生存率的影响进行了详细的统计分析。
本研究纳入了353例LSCC患者和538例对照受试者。多变量Cox回归分析显示患者生存率与IL1RAP rs4624606变体的分布之间存在显著关联：在IL1RAP rs4624606处携带AT基因型的患者死亡风险较低（p = 0.044）。此外，还发现肿瘤大小（T）（p = 0.000）、肿瘤分化程度（G）（p = 0.015）和IL1RAP rs4624606基因型（p = 0.044）是多变量Cox回归分析中预测LSCC患者生存率的有效变量。LSCC的特异性5年生存率为77%。
总之，我们的研究结果表明IL1RAP rs4624606的基因型分布影响LSCC患者的5年生存率。本研究结果有助于在生物学水平上更全面地了解LSCC，从而为鉴定用于LSCC发展的新的特异性和预后性血液标志物提供依据。
